Glycogen Storage Disease Type II (GSD II) Terminated Phase 4 Trials for Methotrexate (DB00563)

Also known as: Acid Maltase Deficiency / Pompe Disease / Acid Maltase Deficiency (AMD) / Pompe's Disease / Pompe-Disease / Glycogen Storage Disease Type II / Glycogen Storage Disease Type II (GSD-II) / Glycogen Storage Disease Type II GSD II / Glycogen Storage Disease Type II;Pompe's Disease / Glycogen Storage Disease Type II-Pompe's Disease / Glycogen Storage Disease Type II Pompe Disease / Cardiac glycogenosis (disorder) / Glycogen storage disease, type II (disorder) / Type II glycogen storage disease / Deficiency of alpha-glucosidase (disorder)

IndicationStatusPhase
DBCOND0041318 (Glycogen Storage Disease Type II (GSD II))Terminated4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00701701Immune Tolerance Induction StudyTreatment